Genmab AS Congressional Trading
According to U.S. congressional financial disclosures filed under the STOCK Act, members of Congress have reported 14 trades in Genmab AS (NASDAQ: GMAB) since 2018, across 5 members, worth an estimated $228.01K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts). 8 buys against 6 sells, a modestly buy-led skew, with Democratic members responsible for 79% of the trades and Republican members 21%. One notable disclosed move was a purchase by Alan Armstrong on March 30, 2026, up 33.0% since. These figures are drawn from public House and Senate periodic transaction reports and reflect what members were required to disclose, not the current market value of any position. Genmab AS's current Quantellect Tide Score is 62 out of 100 (High Tide), Top 28% of universe (3876); the Tide Score is generated algorithmically from public filings and market data and is not investment advice. For the full record, including the month-by-month buy and sell timeline, the party breakdown, top buyers and sellers, and every individual filing, see the Genmab AS (GMAB) stock overview and the complete trade table below.
Data updated
Price & congressional trade timeline
Party breakdown
Genmab AS congressional trading activity
| Politician | Published | Traded | Filed After | Type | Size | Return | Owner | |
|---|---|---|---|---|---|---|---|---|
 Alan Armstrong Senate | Jul 21, 2026 | Mar 30, 2026 | 113 days | BUY |  $1,001 - $15,000 | +33.02% | Self |
Genmab AS (GMAB) congressional trading FAQ
Can members of Congress legally trade Genmab AS (GMAB) stock?
Yes. Members of Congress are permitted to trade individual stocks, including Genmab AS (GMAB), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; it does not imply any trade was improper.
Are congressional Genmab AS (GMAB) trades public?
Yes. Every congressional trade in Genmab AS (GMAB) on this page comes from mandatory public STOCK Act disclosure filings, which are filed with a delay and may be revised.
How many times has Congress traded Genmab AS (GMAB)?
Members of Congress have disclosed 14 trades in Genmab AS (GMAB) worth $228.01K across 5 members, according to public STOCK Act filings.
Which members of Congress have traded Genmab AS (GMAB)?
Recent and active filers of Genmab AS (GMAB) disclosures include Alan Armstrong. The full member-by-member trade list is on this page.
Do Democrats or Republicans trade Genmab AS (GMAB) more?
Across disclosed Genmab AS (GMAB) trades, 79% were by Democrats and 21% by Republicans, led by Democrats (79%).
What is the most recent congressional Genmab AS (GMAB) trade?
The most recent disclosed Genmab AS (GMAB) trade was a purchase by Alan Armstrong, filed Jul 20, 2026.
What is Genmab AS (GMAB)'s Tide Score?
Genmab AS (GMAB) has a Quantellect Tide Score of 62 (High Tide). The Tide Score is a 0-100 read blending price forecast, smart-money flow, technicals, and social sentiment; higher is more bullish.
Browse all stocks Congress tradesCongressional trading overviewGenmab AS (GMAB) stock overview
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. The Tide Score and other figures are generated algorithmically from public filings and market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.